Shandong Jincheng Pharmaceutical Group Co., Ltd

SZSE:300233 Stock Report

Market Cap: CN¥4.2b

Shandong Jincheng Pharmaceutical Group Balance Sheet Health

Financial Health criteria checks 5/6

Shandong Jincheng Pharmaceutical Group has a total shareholder equity of CN¥3.8B and total debt of CN¥599.5M, which brings its debt-to-equity ratio to 15.8%. Its total assets and total liabilities are CN¥5.7B and CN¥1.9B respectively. Shandong Jincheng Pharmaceutical Group's EBIT is CN¥233.5M making its interest coverage ratio 47.5. It has cash and short-term investments of CN¥1.1B.

Key information

15.8%

Debt to equity ratio

CN¥599.47m

Debt

Interest coverage ratio47.5x
CashCN¥1.07b
EquityCN¥3.80b
Total liabilitiesCN¥1.94b
Total assetsCN¥5.74b

Recent financial health updates

Recent updates

Shandong Jincheng Pharmaceutical Group Co., Ltd's (SZSE:300233) Popularity With Investors Is Under Threat From Overpricing

Jun 07
Shandong Jincheng Pharmaceutical Group Co., Ltd's (SZSE:300233) Popularity With Investors Is Under Threat From Overpricing

Shandong Jincheng Pharmaceutical Group's (SZSE:300233) Problems Go Beyond Weak Profit

Apr 04
Shandong Jincheng Pharmaceutical Group's (SZSE:300233) Problems Go Beyond Weak Profit

Shandong Jincheng Pharmaceutical Group Co., Ltd's (SZSE:300233) Shares Climb 29% But Its Business Is Yet to Catch Up

Mar 04
Shandong Jincheng Pharmaceutical Group Co., Ltd's (SZSE:300233) Shares Climb 29% But Its Business Is Yet to Catch Up

Shandong Jincheng Pharmaceutical Group (SZSE:300233) Seems To Use Debt Quite Sensibly

Mar 02
Shandong Jincheng Pharmaceutical Group (SZSE:300233) Seems To Use Debt Quite Sensibly

Financial Position Analysis

Short Term Liabilities: 300233's short term assets (CN¥2.3B) exceed its short term liabilities (CN¥1.4B).

Long Term Liabilities: 300233's short term assets (CN¥2.3B) exceed its long term liabilities (CN¥513.5M).


Debt to Equity History and Analysis

Debt Level: 300233 has more cash than its total debt.

Reducing Debt: 300233's debt to equity ratio has increased from 12.3% to 15.8% over the past 5 years.

Debt Coverage: 300233's debt is well covered by operating cash flow (93%).

Interest Coverage: 300233's interest payments on its debt are well covered by EBIT (47.5x coverage).


Balance Sheet


Discover healthy companies